Author’s response to reviews

Title: Prevention of hypertension in patients with pre-hypertension: PREVER-prevention trial

Authors:

Flávio D Fuchs (ffuchs@hcpa.ufrgs.br)
Sandra C Fuchs (scfuchs@terra.com.br)
Leila B Moreira (lbmoreira@hcpa.ufrgs.br)
Miguel Gus (mgus@terra.com.br)
Antônio C Nóbrega (acnobreagmail.com)
Carlos E Poli-de-Figueiredo (cepolif@pucrs.br)
Décio Mion (demicmion@uol.com.br)
Luiz Bortolotto (hipluiz@incor.usp.br)
Fernanda Consolin-Colombo (hipfernanda@incor.usp.br)
Fernando Nobre (fernando.nobre@uol.com.br)
Eduardo B Coelho (ebcoelho@fmrp.usp.br)
José F Vilela-Martin (vilelamartin@uol.com.br)
Heitor Moreno Jr (hmoreno@uol.com.br)
Evandro J Cesarino (cesarino@fcrp.usp.br)
Roberto Franco (rifranco@fmb.unesp.br)
Andréa A Brandão (andreaabrandao@terra.com.br)
Marcos R de Souza (mrsouza@hc.ufmg.br)
Antônio Luiz P Ribeiro (tom@hc.ufmg.br)
Paulo C Jardim (fvgardim@terra.com.br)
Abrahão Afiune Neto (afiune@cardiol.br)
Luiz César N Scala (lscala@terra.com.br)
Marco Mota (mota-gomes@uol.com.br)
Hilton Chaves (hchavesjr@gmail.com)
João Guilherme Alves (joaoguilherme@imip.org.br)
Dario C Sobral Filho (dsobral@uol.com.br)
Ricardo P Silva (ricardops@secrel.com.br)
José A Figueiredo Neto (jafneto@terra.com.br)
Maria Cláudia Irigoyen (maria.irigoyen@incor.usp.br)
Iran Castro (iacastro@cardiol.br)
André A Steffens (steffens.sul@terra.com.br)
Rosane Schlatter (rschlatter@hcpa.ufrgs.br)
Renato B Mello (renatogbmello@gmail.com)
Francisca Mosele (fmosele@gmail.com)
Flávia Ghizzoni (fghizzoni@hcpa.ufrgs.br)
Otávio Berwanger (otavioberwanger@yahoo.com.br)

Version: 6 Date: 17 January 2011

Author’s response to reviews:
January 16, 2011
To the Editor
Trials

Ref: MS: 5978272194935137 - "Prevention of hypertension in patients with pre-hypertension: PREVER-prevention trial"

Dear Sir,

We are delighted to know that our protocol had very favorable evaluation from such distinguished reviewers. Please, see in the following pages the response to their recommendations. The manuscript was modified accordingly, with highlighted text. Please, let me know if anything else is necessary.

Sincerely yours,

Flávio Danni Fuchs
Corresponding author

Response to the recommendations from Dr Stevo Julius

a. To redefine the primary outcome of hypertension: we followed the recommendation, please see the new definition (BP high in two visits).

b. To maintain non-pharmacological measures throughout the trial: this was the intention, already, and was stated now in methods.

c. To obtain laboratory values at the baseline: this was already planned and is cleared in the revised version.

Response to the recommendations from Dr Luis Ruilope

To extend the follow-up: we will try to do this (and stated now on the revised version) pending on additional funding.